RxDoctor Payments Data

Leah Vandenbosch, PA

Physician Assistant · Williamsville, NYNPI 1013640564

Payments from drug & device makers

$1,530in general payments, 2019–2025

Across 74 payments — averaging $20.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$205
  • Novartis$176
  • E.r. Squibb & Sons, L.L.C.$160
  • AbbVie$126
  • Pfizer$121
  • Lilly USA, LLC$115
  • plus $627 from 14 others

What the payments were for

  • Food & beverage$1,530100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,530 in reported general payments places this provider in the 80th percentile of 11,358 physician assistant providers in New York.

See all physician assistant providers in New York

Medicare billing

Part B allowed, 2024
$11,336
Medicare patients
87
Services billed
197

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban228$306,598
XareltoRivaroxaban88$123,413
OzempicSemaglutide36$39,297
Repatha SureclickEvolocumab29$33,850
EntrestoSacubitril/Valsartan18$30,505
JardianceEmpagliflozin15$25,037
MounjaroTirzepatide12$12,672
Trelegy ElliptaFluticasone/Umeclidin/Vilanter14$11,849
Dabigatran EtexilateDabigatran Etexilate Mesylate23$11,212
Metoprolol Succinate326$8,149
Breo ElliptaFluticasone/Vilanterol11$4,647
Rosuvastatin Calcium177$3,599
Atorvastatin Calcium197$2,799
Digoxin43$1,719
Ezetimibe75$1,702

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$306,598228 claims
Novo NordiskOzempic$48$39,29736 claims
NovartisEntresto$176$30,50518 claims
GSKTrelegy Ellipta, Breo Ellipta$31$16,49625 claims
Lilly USA, LLCMounjaro$115$12,67212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 11,358 physician assistant providers in New York.

Other physician assistant in Williamsville

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →